These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23107589)

  • 1. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer.
    Ataie-Kachoie P; Pourgholami MH; Morris DL
    Cytokine Growth Factor Rev; 2013 Apr; 24(2):163-73. PubMed ID: 23107589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene of the month: Interleukin 6 (IL-6).
    Ataie-Kachoie P; Pourgholami MH; Richardson DR; Morris DL
    J Clin Pathol; 2014 Nov; 67(11):932-7. PubMed ID: 25031389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 signaling pathway in targeted therapy for cancer.
    Guo Y; Xu F; Lu T; Duan Z; Zhang Z
    Cancer Treat Rev; 2012 Nov; 38(7):904-10. PubMed ID: 22651903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.
    Neurath MF; Finotto S
    Cytokine Growth Factor Rev; 2011 Apr; 22(2):83-9. PubMed ID: 21377916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance.
    Zhang C; Zhang X; Chen XH
    Clin Rev Allergy Immunol; 2014 Oct; 47(2):163-73. PubMed ID: 24647663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 as a therapeutic target in candidate inflammatory diseases.
    Nishimoto N
    Clin Pharmacol Ther; 2010 Apr; 87(4):483-7. PubMed ID: 20182422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease.
    Sikorski K; Czerwoniec A; Bujnicki JM; Wesoly J; Bluyssen HA
    Cytokine Growth Factor Rev; 2011 Aug; 22(4):211-9. PubMed ID: 21752694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases.
    Rincon M
    Trends Immunol; 2012 Nov; 33(11):571-7. PubMed ID: 22883707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Interleukin-6 Signaling in Clinic.
    Kang S; Tanaka T; Narazaki M; Kishimoto T
    Immunity; 2019 Apr; 50(4):1007-1023. PubMed ID: 30995492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.
    Rath T; Billmeier U; Waldner MJ; Atreya R; Neurath MF
    Arch Toxicol; 2015 Apr; 89(4):541-54. PubMed ID: 25632846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.
    Mori T; Miyamoto T; Yoshida H; Asakawa M; Kawasumi M; Kobayashi T; Morioka H; Chiba K; Toyama Y; Yoshimura A
    Int Immunol; 2011 Nov; 23(11):701-12. PubMed ID: 21937456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer.
    Chalaris A; Garbers C; Rabe B; Rose-John S; Scheller J
    Eur J Cell Biol; 2011; 90(6-7):484-94. PubMed ID: 21145125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melatonin as a new possible anti-inflammatory agent.
    Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
    J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting IL-23 in human diseases.
    D'Elios MM; Del Prete G; Amedei A
    Expert Opin Ther Targets; 2010 Jul; 14(7):759-74. PubMed ID: 20536413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term exposure to IL-1beta enhances Toll-IL-1 receptor-mediated inflammatory signaling in murine airway hyperresponsiveness.
    Zhang Y; Xu CB; Cardell LO
    Eur Cytokine Netw; 2009 Sep; 20(3):148-56. PubMed ID: 19825525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6 signal transduction and its physiological roles: the signal orchestration model.
    Kamimura D; Ishihara K; Hirano T
    Rev Physiol Biochem Pharmacol; 2003; 149():1-38. PubMed ID: 12687404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
    Rose-John S; Scheller J; Elson G; Jones SA
    J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-18: biological properties and clinical implications.
    Lebel-Binay S; Berger A; Zinzindohoué F; Cugnenc P; Thiounn N; Fridman WH; Pagès F
    Eur Cytokine Netw; 2000 Mar; 11(1):15-26. PubMed ID: 10705295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IRAK4 in TLR/IL-1R signaling: possible clinical applications.
    Li X
    Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.